Cost impact of replacing Efavirenz with Dolutegravir in first-line treatment of adults in South Africa

By  Gesine Meyer-Rath  Sithabiso Masuku  |  | 

The South African Department of Health (DOH) has decided to replace the antiretroviral therapy (ART) regimen for adults on first line by replacing efavirenz (EFV) with the better tolerated dolutegravir (DTG). We were tasked by DOH to assess the impact of this change on the cost of the national ART programme.

Publication details

PDF